Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.
Biomarkers
Immunogenicity
Pharmacokinetics (PK)
Cell-Based Assays
Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for biotherapeutics innovation.
Biosimilars
Gene Therapy
Antibody Drug Conjugates (ADCs)
Immuno-oncology
September 5, 2019 | 10:00am EDT / 15:00 BST | Co-Hosted with Bioanalysis Zone
With the question ‘should we qualify or validate an exploratory biomarker assay before sample testing?’ in mind, BioAgilytix’s Dr. Afshin Safavi will review and discuss the latest scientific and regulatory considerations for the analytical validation of assays for fluid-based biomarkers used in the qualification of drug development tools (DDTs).
Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.
Quick links to our latest content offerings:
August 21, 2019Gene Therapy Trends: Conditional Approval of Zynteglo Brings Ex Vivo Gene Therapy Into Focus
August 13, 2019C-Path “Points to Consider Document” Clarifies Bioanalytical Assay Validation in Support of Clinical Biomarker Qualification
August 15, 2019Thomas Zajkowski Joins BioAgilytix Leadership Team as Chief Financial Officer
August 14, 2019BioAgilytix Named to Inc. Magazine’s Inc. 5000 List of Fastest-Growing Private U.S. Companies for Sixth Time
May 9, 2018Evaluating the Immunogenicity of Antibody–drug Conjugates
April 16, 2018Strategies for Development and Validation of Neutralizing Antibody Assays Supporting Biosimilars
Services
Platforms
Choose your region to learn more about our premier large
molecule global services and the BioAgilytix location closest to you.
